Ca001-050 - A Randomized, Open-Label Phase 2 Clinical Trial Of Bms-986012 In Combination With Carboplatin, Etoposide, And Nivolumab As First-Line Therapy In Extensive-Stage Small Cell Lung Cancer
Posted Date: Mar 31, 2022
- Investigator: Jennifer Leddon
- Specialties: Cancer, Lung Cancer, Oncology
- Type of Study: Drug
The purpose of this study is to demonstrate that treatment with BMS-986012 in combination with carboplatin, etoposide, and nivolumab will have acceptable safety and tolerability and will improve progression-free survival compared with carboplatin, etoposide, and nivolumab alone in newly diagnosed participants with extensive-stage small cell lung cancer (ES-SCLC).
Criteria:
To Be Eligible: Histologically Or Cytologically Documented Extensive-Stage Small Cell Lung Cancer (Es-Sclc) And Extensive-Stage Disease, Must Provide A Fresh Tumor Biopsy From The Primary Disease Site (When Possible) Or From Any Metastatic Site When The Primary Site Is Not Available, Eastern Cooperative Oncology Group Performance Status (Ecog Ps) 0 Or 1, At Least 1 Measurable Lesion By Computed Tomography (Ct) Or Magnetic Resonance Imaging (Mri) Per Response Evaluation Criteria In Solid Tumors Version 1.1,Adequate Hematologic And End Organ Function, No Prior Chemotherapy, Radiation Therapy, Or Biologic Therapy For Small Cell Lung Cancer (Sclc) For First-Line Treatment, No Symptomatic Brain Or Other Central Nervous System (Cns) Metastases, No Paraneoplastic Autoimmune Syndrome Requiring Systemic Treatment, No History Of Idiopathic Pulmonary Fibrosis, Drug-Induced Pneumonitis, Idiopathic Pneumonitis, Organizing Pneumonia, Or Evidence Of Active Pneumonitis On Screening Chest Ct Scan, No Grade = 2 Peripheral Sensory Neuropathy At Study Entry, No Significant Uncontrolled Cardiovascular Disease, No Active, Known Or Suspected Autoimmune Disease Or Inflammatory Disorder
Keywords:
Lung, Cancer, Phase 2
For More Information:
Uc Cancer Center
5135847698
cancer@uchealth.com